secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K
Filed at:   2026-09-24T11:05:32+00:00
Accession:  0001628280-26-063316
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vistagen reports positive fasedienol data in very severe social anxiety at Psych Congress 2026
--------------------------------------------------------------------------------

- Post-hoc PALISADE-4 Phase 3 analysis showed statistically significant SUDS improvement in very severe SAD (LSAS >=95) despite missed primary endpoint in overall population.
- Phase 2a repeat-dose study prespecified analysis: significant SUDS improvement after single dose; greater numerical improvement after second dose taken 10 minutes later.
- Second-dose data also showed significant improvements in anticipatory anxiety pre-PSC in both overall and very severe populations.
- Safety in very severe subgroup consistent with prior trials; no serious drug-related signals identified.
- Data presented at Psych Congress 2026 in New Orleans; supports fasedienol's potential for LSAS >=95 patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000162828026063316/0001628280-26-063316-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000162828026063316/vtgn-20260924.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-063316

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer